

FINANCIAL STATEMENTS (Unaudited)

For the period from 01.07.2024 to 31.12.2024



THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,

Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)
As at 31 December 2024

		Amount in Taka	
		31 December 2024	30 June 2024
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04.A	4,166,039,959	3,888,791,104
Capital Work-In-Progress	05.A	2,565,861,461	2,628,798,080
Right-of-Use Assets	05.B	1,494,425,310	1,138,897,211
Advances, Deposits & Prepayments	10.A.1	45,637,119	57,877,245
Financial Assets	06.A	8,911,000	9,048,009
		51,305,068	54,170,559
Current Assets :		2,537,193,506	2,620,323,446
Financial Assets	7.B	78,912,666	166,791,561
Inventories	08.A	1,598,717,674	1,585,350,954
Trade and Other Receivables	09.A	198,865,957	202,514,000
Advances, Deposits & Prepayments	10.A	380,060,922	300,437,038
Cash & Cash Equivalents	11.A	280,646,287	365,229,893
TOTAL ASSETS		6,703,233,465	6,509,114,550
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Equity attributable to the owners of the company:			
Share Capital	12	3,593,303,060	3,497,480,774
Tax Holiday Reserve	13	312,436,270	312,436,270
FVOCI Reserve	14	4,392,110	4,392,110
Retained Earnings	15.A	(11,361,536)	(8,610,720)
		3,287,836,215	3,189,263,114
Non Controlling Interests	15.B	36,338,953	35,879,719
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16.A	844,684,788	657,654,587
Employee Benefit Obligations	17.A	708,915,066	530,490,522
Lease Liabilities	17.B	1,696,257	1,185,181
Deferred Tax Liabilities	19	25,990,336	24,798,698
		108,083,129	101,180,186
Current Liabilities:		2,228,906,664	2,318,099,470
Short Term Finance	20.A	937,313,747	1,242,553,919
Current Portion of Long Term Finance	21	31,174,280	62,301,769
Lease Liabilities	17.B	12,173,322	25,538,281
Trade and Other Payable	22.A	775,279,136	663,984,345
Unclaimed Dividend	22.B	78,055,042	39,140,597
Income Tax Payables	23.A	394,911,138	284,580,559
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		6,703,233,465	6,509,114,550
Net Assets Value (NAV) Per Share	31.A	115.01	111.94


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
 25 January 2025


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)
For the Half-Year ended 31 December 2024

		Amount in Taka			
Notes		For the half-year (1 July 2024 to 31 December 2024)	For the half-year (1 July 2023 to 31 December 2023)	For the Quarter (1 October 2024 to 31 December 2024)	For the Quarter (1 October 2023 to 31 December 2023)
REVENUE	24.A	5,930,046,291	5,825,826,125	3,174,104,435	2,930,299,404
Cost of goods sold	24.C	(3,534,028,829)	(3,470,509,438)	(1,899,115,951)	(1,779,473,907)
GROSS PROFIT		2,396,017,462	2,355,316,687	1,274,988,484	1,150,825,497
OPERATING EXPENSES		(1,930,906,619)	(1,817,546,911)	(987,014,146)	(869,493,395)
Administrative expenses	25.A	(134,115,019)	(126,016,106)	(74,982,945)	(68,964,675)
Selling and Distribution expenses	26.A	(1,796,791,600)	(1,691,530,805)	(912,031,201)	(800,528,720)
OPERATING PROFIT		465,110,843	537,769,776	287,974,338	281,332,102
Finance charges	34	(38,753,623)	(23,763,935)	(20,151,925)	(11,685,738)
Other income		11,728,648	9,321,580	3,333,220	3,293,966
Profit before WPPF and welfare fund		438,085,868	523,327,421	271,155,633	272,940,331
Workers' P.P. fund and welfare fund	27.A	(25,290,807)	(25,095,294)	(14,730,378)	(13,115,248)
PROFIT BEFORE TAX		412,795,062	498,232,128	256,425,256	259,825,083
Income tax expenses	28.A	(116,927,876)	(125,767,754)	(45,470,421)	(50,351,400)
PROFIT FOR THE THE PERIOD		295,867,185	372,464,373	210,954,834	209,473,682
PROFIT /(LOSS) ATTRIBUTABLE TO:					
Owners of the Company		295,407,951	372,122,963	210,773,082	209,275,459
Non-controlling interest		459,234	341,411	181,754	198,223
		295,867,185	372,464,373	210,954,836	209,473,682
Other Comprehensive Income:					
Change in fair value of Marketable Securities	29	(3,056,462)	(41,200)	(8,290,512)	1,816,504
Less: Deferred tax		(305,646)	(4,120)	(829,051)	181,650
Total other comprehensive income for the period, net of tax		(2,750,816)	(37,080)	(7,461,461)	1,634,854
Total Comprehensive Income for the period		293,116,370	372,427,293	203,493,374	211,108,536
Total Comprehensive Income Attributable to:					
Owner of the Company		292,657,136	372,085,883	203,311,622	210,910,313
Non-controlling interest		459,234	341,411	181,754	198,223
		293,116,370	372,427,293	203,493,376	211,108,536
Earnings Per Share (EPS)	30.A	9.47	11.92	6.75	6.70
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2024

Amount In Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,706,202,764	35,051,367	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	670,522,122	828,351	665,006,105
Dividend for the year 30 June 2023 (Cash-60%) Issued during the year				(187,461,762)	-	(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 31 December, 2024			(2,750,816)	295,407,951	459,234	293,116,370
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Balance as at 31 December 2024	312,436,270	4,392,110	(11,361,537)	3,287,836,215	36,338,953	3,629,642,013

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2023

Amount In Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2022	312,436,270	4,392,110	(685,588)	2,288,247,972	20,659,192	2,625,049,957
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2023			(1,580,764)	605,416,544	392,175	604,227,956
Dividend for the year 30 June 2022 (Cash-60%) Issued during the year				(187,461,762)		(187,461,762)
					14,000,000	14,000,000
Balance as at 30 June 2023	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,368	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 31 December, 2023			(37,080)	372,122,963	341,411	372,427,293
Dividend for the year 30 June, 2023 (Cash-60%)				(187,461,762)		(187,461,762)
Balance as at 31 December 2023	312,436,270	4,392,110	(2,303,432)	2,890,863,955	35,392,778	3,240,781,683


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)
For the Half-Year ended 31 December 2024

	Amount in Taka	
	Half-year ended 31.12.2024	Half-year ended 31.12.2023
Cash Flows From Operating Activities:		
Received from revenue and others	5,933,704,334	5,796,279,431
Payment for operation, expenses & others	(5,280,487,091)	(5,325,400,595)
Miscellaneous income	903,243	555,581
Cash generated from operations	654,120,486	471,434,417
Income tax paid	(78,685,686)	(105,483,476)
Payment for Financial charges	(36,620,120)	(20,611,828)
Net cash provided by operating activities	538,814,680	345,339,113
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(387,287,968)	(416,325,795)
Proceeds from sale of property, plant equipment	-	359,793
Dividend Received/ IBBL-MPB	-	198,750
Acquisition of financial assets	90,643,806	(43,302,896)
Received from bank	3,643,126	2,622,814
Net cash used in investing activities	(293,001,036)	(456,447,334)
Cash Flows From Financing Activities:		
Payment of dividend	(157,920,405)	(145,471,508)
Payment of lease liabilities	(14,486,825)	(13,998,280)
Long term finance received/(paid) from bank (Net)	178,424,544	33,260,671
Short term finance received/(paid) from bank (Net)	(336,367,661)	279,186,056
Net cash provided by financing activities	(330,350,348)	152,976,939
Increase/(decrease) in cash and cash equivalents	(84,536,704)	41,868,719
Cash and cash equivalents at 1 July	365,229,893	232,227,915
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	(46,902)	1,543,202
Cash and cash equivalents at 31 December	280,646,287	275,639,836
NOCFPS (Note 32.A)	17.25	11.05


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31 December 2024

Amount in Taka

	Notes	31 December 2024	30 June 2024
ASSETS:			
Non-Current Assets:		4,165,865,548	3,927,192,582
Property, Plant and Equipment	04	2,339,093,707	2,402,132,734
Capital Work-In-Progress	05	847,099,183	580,044,566
Right-of-Use Assets	05.B	45,537,119	57,877,245
Financial Assets	06	22,305,068	25,170,559
Advances, Deposits & Prepayments	10.1	8,661,000	8,798,009
Investment in Subsidiaries	07	903,169,470	853,169,470
		2,110,752,854	2,150,287,884
Current Assets :			
Financial Assets	07.A	22,500,000	89,500,000
Inventories	08	1,365,999,656	1,338,777,834
Trade and Other Receivables	09	174,998,573	167,308,708
Advances, Deposits & Prepayments	10.1	326,244,987	242,225,497
Cash & Cash Equivalents	11	221,009,638	312,475,845
TOTAL ASSETS		6,276,618,402	6,077,480,466
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:		3,643,331,325	3,475,989,493
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(11,361,536)	(8,610,720)
Retained Earnings	15	3,337,864,481	3,167,771,833
LIABILITIES:			
Non-Current Liabilities:		631,488,701	534,277,576
Long Term Finance	16	497,598,524	409,007,995
Employee Benefit Obligations	17	1,696,257	1,185,181
Lease Liabilities	17.B	25,990,336	24,798,698
Deferred Tax Liabilities	18	106,203,585	99,285,702
Current Liabilities:		2,001,798,375	2,067,213,397
Short Term Finance	20	908,938,633	1,122,170,475
Current Portion of Long Term Finance	21	31,174,280	62,301,769
Lease Liabilities	17.B	12,173,322	25,538,281
Trade and Other Payables	22	609,266,513	562,195,866
Unclaimed Dividend	22.B	78,055,042	39,140,597
Income Tax Payables	23	362,190,586	255,866,409
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		6,276,618,402	6,077,480,466
Net Assets Value (NAV) Per Share	31	116.61	111.25


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)
For the Half-Year ended 31 December 2024

					Amount in Taka
	Notes	For the half-year (1 July 2024 to 31 December 2024)	For the half-year (1 July 2023 to 31 December 2023)	For the Quarter (1 October 2024 to 31 December 2024)	For the Quarter (1 October 2023 to 31 December 2023)
REVENUE	24	5,409,918,654	5,163,125,414	2,866,113,043	2,607,325,407
Cost of goods sold	24.B	(3,223,746,603)	(3,093,742,876)	(1,724,667,639)	(1,595,659,063)
GROSS PROFIT		2,186,172,051	2,069,382,538	1,141,445,404	1,011,666,344
OPERATING EXPENSES		(1,651,927,422)	(1,552,949,449)	(840,941,017)	(738,289,802)
Administrative expenses	25	(112,648,751)	(111,548,921)	(62,985,465)	(60,484,643)
Selling & Distribution expenses	26	(1,539,278,671)	(1,441,400,528)	(777,955,552)	(677,805,159)
OPERATING PROFIT		534,244,629	516,433,089	300,504,387	273,376,542
Finance charges	34	(38,753,623)	(23,763,935)	(20,151,925)	(11,705,966)
Other income		8,366,101	7,082,181	1,735,641	1,997,133
Profit before WPPF and welfare fund		503,857,107	499,751,336	282,088,103	263,667,710
Workers' P.P. fund and welfare fund	27	(23,993,196)	(23,797,683)	(13,432,767)	(12,555,606)
PROFIT BEFORE TAX		479,863,911	475,953,653	268,655,336	251,112,104
Income tax expenses	28	(112,936,413)	(117,486,595)	(43,786,633)	(46,568,466)
PROFIT FOR THE THE PERIOD		366,927,499	358,467,058	224,868,703	204,543,638
Other Comprehensive Income:					
Change in fair value of Marketable Securities	29	(3,056,462)	(41,200)	2,177,588	(41,200)
Less: Deferred tax		(305,646)	(4,120)	217,759	(4,120)
Total other comprehensive income for the period, net of tax		(2,750,816)	(37,080)	1,959,829	(37,080)
Total Comprehensive Income for the period		364,176,683	358,429,978	226,828,533	204,506,558
Earnings Per Share (EPS)	30	11.74	11.47	7.26	6.55
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2024

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	655,067,965	648,723,597
Dividend for the year 30 June, 2023 (Cash-60%)				(187,461,762)	(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,493
Statement of profit or loss and other Comprehensive Income for period ended 31 December 2024			(2,750,816)	366,927,499	364,176,683
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 31 December 2024	312,436,270	4,392,110	(11,361,536)	3,337,864,481	3,643,331,325

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2023

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2022	312,436,270	4,392,110	(685,588)	2,307,686,156	2,623,828,948
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2023			(1,580,764)	579,941,235	578,360,472
Dividend for the period 30 June 2022 (Cash - 60%)				(187,461,762)	(187,461,762)
Balance as at 30 June 2023	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 31 December 2023			(37,080)	358,467,058	358,429,978
Dividend for the year 30 June 2023 (Cash-60%)				(187,461,762)	(187,461,762)
Balance as at 31 December 2023	312,436,270	4,392,110	(2,303,432)	2,871,170,925	3,185,695,873


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025



Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CASH FLOWS (Unaudited)
For the Half-Year ended 31 December 2024

	Amount in Taka	
	Half-year ended 31.12.2024	Half-year ended 31.12.2023
Cash Flows From Operating Activities:		
Received from revenue and others	5,402,228,789	5,187,000,556
Payment for operation, expenses & others	(4,782,358,826)	(4,675,582,601)
Miscellaneous income	903,243	555,581
Cash generated from operations	620,773,206	511,973,536
Income tax paid	(76,940,255)	(100,963,381)
Payment for Financial charges	(36,620,120)	(20,611,828)
Net cash provided by operating activities	507,212,831	390,398,327
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(290,501,594)	(219,988,087)
Proceeds from sale of property, plant equipment	-	359,793
Investment in Subsidiary	(50,000,000)	(150,000,000)
Dividend Received/ IBBL-MPB	-	198,750
Acquisition of financial assets	69,865,491	(43,302,896)
Received from bank	-	203,415
Net cash used in Investing activities	(270,636,103)	(412,529,025)
Cash Flows From Financing Activities:		
Payment of dividend	(157,920,405)	(145,471,508)
Payment of lease liabilities	(14,306,825)	(13,998,280)
Long term finance received/(paid) from bank (Net)	88,590,529	(8,935,411)
Short term finance received/(paid) from bank (Net)	(244,359,331)	229,607,620
Net cash provided by financing activities	(327,996,033)	61,202,421
Increase/(decrease) in cash and cash equivalents	(91,419,305)	39,071,724
Cash and cash equivalents at 1 July	312,475,845	176,832,762
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	(46,902)	1,543,202
Cash and cash equivalents at 31 December	221,009,638	217,447,688
NOCFPS (Note 32)	16.23	12.50


Chief Financial Officer


Company Secretary


Managing Director


Director


Chairman

Dated, Dhaka .
25 January 2025

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
SELECTED NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)
For the Half-Year ended 31 December 2024

SELECTED EXPLANATORY NOTES:

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd.; The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

2 Basis of preparation

2.1 Statement of compliance

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2024.

2.2 Date of authorisation

The interim financial statements were authorised for issue by the Board of Directors on 25 January 2025 for publication.

2.3 Functional and presentation currency

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

2.4 Significant accounting policies

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2024.

3 Significant Deviations

3.1 EARNINGS PER SHARE (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended 31 December 2024 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2023 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

3.2 SUBSEQUENT EVENTS:

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

3.3 INCREASE IN EARNINGS PER SHARE (EPS):

As a result of increase in operating expenses, EPS has been decreased during current period over last reporting period.

3.4 INCREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):

Net operating cash flow per share (NOCFPS) increased during current period over last reporting period due to decrease in payment for cost & expenses & others.

3.5 INCOME TAX:

Payment of income tax decreased due to decrease in tax rate and net profit. advance income tax also increased due to payment for quarterly installment.

3.6 PAYMENT FOR FIXED ASSETS:

Payment for purchases of fixed assets decreased due to decrease in addition of fixed assets during this reporting period.

3.7 Other income increased during the period due to increase in revenue from toll production charge.

3.8 Payment of dividend increased due to declaration of higher dividend on last year's income during the reporting period.

3.9 FINANCE CHARGE:

Finance charge during the reporting period increased due to increase of long term loan.

3.10 INCREASE IN REVENUE:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

3.11 CASH FLOWS FROM INVESTING ACTIVITIES:

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets and payment of share capital of The IBN SINA API Industry Ltd. than the same period of last year.

3.12 SHORT TERM FINANCE:

Short term finance decreased during the period due to decrease in import of raw materials under sight LC arrangement.

3.13 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

	31 December 2024	30 June 2024
04. PROPERTY, PLANT AND EQUIPMENT:		
Cost :		
Opening balance	3,956,915,644	3,671,727,462
Addition during the period	23,446,976	286,202,084
Disposal/Adjustment during the period	(1,851,770)	(1,013,902)
Closing balance	3,978,510,850	3,956,915,644
Accumulated Depreciation:		
Opening balance	1,554,782,910	1,377,611,748
Charged during the period	85,782,464	178,122,358
Disposal/Adjustment during the period	(1,148,230)	(951,195)
Closing balance	1,639,417,143	1,554,782,910
Closing balance of written Down Value (WDV)	2,339,093,707	2,402,132,734

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:

The IBN SINA Pharmaceutical Industry PLC	2,339,093,707	2,402,132,734
The IBN SINA API Industry Ltd.	145,356,745	146,098,539
The IBN SINA Natural Medicine Ltd.	81,411,009	80,566,807
	2,565,861,461	2,628,798,080

05. CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	366,379,612	131,190,647
Addition during the period	197,634,712	366,379,612
Less: Transferred to property plant and equipment	-	(131,190,647)
Closing balance	564,014,324	366,379,612
B) Machinery in transit and installation		
Opening balance	213,664,954	121,548,825
Addition during the period	131,590,764	274,985,002
Less: Transferred to property, plant and equipment	(62,170,859)	(182,868,873)
Closing balance	283,084,859	213,664,954
	847,099,183	580,044,566

i) Some new construction is under process to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. The amount in machinery in transit represents the amount for opening the LC for the procurement of Factory machineries for newly constructed factory building and increasing production capacity of existing factory which are not received yet by the company.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	465,469,776	198,768,487
Addition during the period	225,669,318	397,891,936
Less: Transferred to property plant and equipment	-	(131,190,647)
Closing balance	691,139,094	465,469,776
B) Machinery in transit and installation		
Opening balance	673,427,435	373,701,080
Addition during the period	192,029,640	482,595,228
Less: Transferred to property, plant and equipment	(62,170,859)	(182,868,873)
Closing balance	803,286,216	673,427,435
	1,494,425,310	1,138,897,211

		Amount in Taka	
		31 December 2024	30 June 2024
05.B RIGHT-OF-USE ASSETS:			
Opening balance		130,252,602	130,252,602
Addition during the period		-	-
Disposal/Adjustment during the period		-	-
Closing balance		130,252,602	130,252,602
Accumulated Depreciation:			
Opening balance		72,375,357	47,385,679
Addition during the period		12,340,126	24,989,678
Disposal/Adjustment during the period		-	-
Closing balance		84,715,483	72,375,357
Closing balance of Written Down Value (WDV)		45,537,119	57,877,245
06. FINANCIAL ASSETS (NON-CURRENT PORTION):			
Exim Bank PLC		2,736,000	3,154,000
First Security Islami Bank PLC		10,460,100	12,531,750
Shahjalal Islami Bank Ltd.		1,884,900	1,843,700
Al-Arafah Islami Bank PLC		2,108,925	2,552,340
Social Islami Bank PLC		1,528,058	1,267,594
Islami Bank Bangladesh PLC (IBBL) in MPB		3,587,085	3,821,175
		22,305,068	25,170,559
The above investment in marketable securities are designated as Fair Value through Other Comprehensive Income (FVOCI) by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. The shares of Exim Bank Ltd. and IBBL-MPB are listed in Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd. The whole investment in shares of both the companies are in DSE only.			
06.A CONSOLIDATED FINANCIAL ASSETS (NON-CURRENT PORTION):			
Exim Bank PLC		2,736,000	3,154,000
First Security Islami Bank PLC		10,460,100	12,531,750
Shahjalal Islami Bank Ltd.		1,884,900	1,843,700
Al-Arafah Islami Bank PLC		2,108,925	2,552,340
Social Islami Bank PLC		1,528,058	1,267,594
Islami Bank Bangladesh PLC (IBBL) in MPB		3,587,085	3,821,175
Investment in API Industrial Park Services Ltd.		29,000,000	29,000,000
		51,305,068	54,170,559
07 INVESTMENT IN SUBSIDIARIES :			
The IBN SINA API Industry Ltd.		599,999,800	549,999,800
The IBN SINA Natural Medicine Ltd.		238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.		65,000,000	65,000,000
		903,169,470	853,169,470
i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk.5 crore have been paid as a part of share capital. ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company. iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company.			
07.A FINANCIAL ASSETS (CURRENT PORTION):			
Opening balance (Investment in MTD)		89,500,000	22,500,000
During the period/year		-	67,000,000
MTDR-Closed during the period		(67,000,000)	-
Investment in Mudaraba Term Deposit		22,500,000	89,500,000
07.B CONSOLIDATED FINANCIAL ASSETS (CURRENT PORTION):			
Opening Balance		166,791,561	95,786,254
During the period-Closed		(87,878,895)	71,005,307
Investment in Mudaraba Term Deposit		78,912,666	166,791,561

	Amount in Taka	
	31 December 2024	30 June 2024
08. INVENTORIES:		
Raw materials	460,065,067	447,551,352
Packing materials	155,936,884	149,636,336
Work-in-process	112,418,462	103,450,764
Finished goods	361,169,358	356,044,770
Physicians' samples	4,945,192	4,821,092
Pad & literature	4,521,896	4,358,886
Spares & stores	399,385	372,575
Indirect materials	480,558	476,104
Printing & stationery	416,138	403,708
Laboratory chemicals	249,019	247,558
Material in transit	265,397,697	271,414,689
	<u>1,365,999,656</u>	<u>1,338,777,834</u>

- i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces, some are in box and some are in kg, gram, milli gram, ton, liter and pcs as such quantity can not be inserted.
- ii) There is no damage goods or slow moving item in the inventory list.
- iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.
- iv) Inventory for raw materials, packing materials, Work In Process, Finished goods and material in transit increased during the period for ensuring smooth supply of goods to meetup increased customer demand.

08.A CONSOLIDATED INVENTORIES:

Raw materials	534,782,412	593,235,375
Packing materials	191,137,253	194,418,191
Work-in-process	126,154,074	114,219,828
Finished goods	467,005,540	398,534,726
Physicians' samples	8,173,702	7,669,314
Pad & literature	4,521,896	4,358,886
Spares & stores	399,385	372,575
Indirect materials	480,558	476,104
Printing & stationery	416,138	403,708
Laboratory chemicals	249,019	247,558
Material in transit	265,397,697	271,414,689
	<u>1,598,717,674</u>	<u>1,585,350,954</u>

09. TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	171,058,100	160,620,563
Receivable from provident fund (PF)	99,706	399,752
Dividend receivable	-	1,869,684
Profit receivable from MTD	2,016,775	3,764,794
Other receivable-toll charge	1,823,992	653,915
	<u>174,998,573</u>	<u>167,308,708</u>

- i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.
- ii) Other receivable increased during the period due to increased toll charge.
- iii) Trade receivable increased during the period due to increase in sales revenue and customer types.

09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	194,915,484	195,825,855
Receivable from provident fund (PF)	99,706.00	399,752
Dividend receivable	-	1,869,684
Profit receivable from MTD	2,016,775	3,764,794
Other receivable-toll charge	1,823,992	653,915
	<u>198,855,957</u>	<u>202,514,000</u>

		Amount in Taka	
		31 December 2024	30 June 2024
10. ADVANCES, DEPOSITS and PREPAYMENTS :			
a. Advances against			
Salary	6,026,212	6,068,335	
Expenses/works/others	10,957,015	11,010,215	
Depot rent	6,461,323	7,407,181	
Motor cycles-to employees	8,612,562	8,736,752	
Others	715,298	706,533	
	32,772,410	33,929,016	
b. Income tax			
Opening balance	200,028,807	165,887,969	
Addition	76,940,255	188,898,585	
Adjusted during the period	-	(154,757,747)	
	276,969,062	200,028,807	
c. Deposits			
Security money	25,164,248	17,065,542	
d. Pre payments			
Value Added Tax	266	140	
	334,905,987	251,023,506	
10.1 MATURITY ANALYSIS:			
Realizable/adjustable within one year.	326,244,987	242,225,497	
Realizable/adjustable after one year.	8,661,000	8,798,009	
	334,905,987	251,023,506	
10.A CONSOLIDATED ADVANCES, DEPOSITS AND PREPAYMENTS :			
a. Advances against			
Salary	10,391,745	9,991,335	
Expenses/works/others	11,580,906	14,866,965	
Depot rent	6,461,323	7,407,181	
Motor cycles-to employees	30,269,167	33,774,284	
Others	1,882,132	1,843,151	
	60,585,273	67,882,916	
b. Income tax			
Opening balance	223,481,751	174,659,013	
Addition	78,685,685	203,580,485	
Adjusted during the period	-	(154,757,747)	
	302,167,436	223,481,751	
c. Deposits			
Security money	26,218,945	18,120,239	
d. Pre payments			
Value Added Tax	266	140	
	388,971,921	309,485,047	
The company did not give any advance, deposit and prepayment to the director's of the company, subsidiaries and other connected parties and employees advances are realised in normal course of business.			
10.A.1 MATURITY ANALYSIS:			
Realizable/adjustable within one year.	380,060,922	300,437,038	
Realizable/adjustable after one year.	8,911,000	9,048,009	
	388,971,922	309,485,047	
11. CASH AND CASH EQUIVALENTS:			
a. Cash in hand	7,791,320	6,553,245	
b. Cash at bank	209,683,318	302,422,600	
c. Imprest cash	3,535,000	3,500,000	
	221,009,638	312,475,845	

		Amount in Taka	
		31 December 2024	30 June 2024
11.A CONSOLIDATED CASH AND CASH EQUIVALENTS:			
a. Cash in hand		7,791,320	6,893,349
b. Cash at bank		269,319,967	354,706,544
c. Imprest cash		3,535,000	3,630,000
		<u>280,646,287</u>	<u>365,229,893</u>
12. SHARE CAPITAL:			
Authorized:			
50,000,000 Ordinary Shares of Tk. 10 each		<u>500,000,000</u>	<u>500,000,000</u>
Issued, Subscribed & Paid-Up :			
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash		<u>312,436,270</u>	<u>312,436,270</u>
The Shareholdings consist of :			
Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution (I.C.B)	250	6,093,488	19.50%
General Public	12,777	11,306,827	36.19%
	<u>13,028</u>	<u>31,243,627</u>	<u>100.00%</u>
The distribution schedule showing the number of share holders and their share holdings as on 30.12.2024 are as follows:			
Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	10,045	1,826,397	5.97%
500 to 5,000 shares	2,567	3,878,300	11.36%
5,001 to 10,000 shares	198	1,433,686	4.69%
10,001 to 20,000 shares	118	1,605,038	4.73%
20,001 to 30,000 shares	32	764,524	2.98%
30,001 to 40,000 shares	16	555,771	2.00%
40,001 to 50,000 shares	11	505,115	1.83%
Above 50,000 shares	41	20,674,796	66.43%
	<u>13,028</u>	<u>31,243,627</u>	<u>100.00%</u>
The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk.286.80 in the Dhaka Stock Exchange Limited on 30.12.2024 and at Tk.287.00 in the Chittagong Stock Exchange Limited on 30.12.2024 respectively.			
13. TAX HOLIDAY RESERVE:		<u>4,392,110</u>	<u>4,392,110</u>
This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.			
14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:			
Closing market value of marketable securities		22,305,068	25,170,559
Less: Cost of marketable securities		34,928,997	34,738,026
Unrealized gain before adjustment of deferred tax		<u>(12,623,928)</u>	<u>(9,567,467)</u>
Less: Deferred tax on unrealized gain/(loss)		1,262,393	956,747
Net unrealized gain/(loss) on marketable securities		<u>(11,361,536)</u>	<u>(8,610,720)</u>
15. RETAINED EARNINGS:			
Opening Balance		3,167,771,833	2,700,165,629
Dividend paid		(196,834,850)	(187,461,762)
Add : Net profit during the period		366,927,499	655,067,965
		<u>3,337,864,481</u>	<u>3,167,771,833</u>
15A. CONSOLIDATED RETAINED EARNINGS:			
Opening Balance		3,189,263,114	2,706,202,754
Dividend paid		(196,834,850)	(187,461,762)
Add: Net profit during the period		295,407,951	670,522,122
		<u>3,287,836,215</u>	<u>3,189,263,114</u>
15B. NON CONTROLLING INTERESTS:			
The IBN SINA API Industry Ltd.		200	200
The IBN SINA Natural Medicine Ltd.		3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)		35,000,000	35,000,000
Add: Share of Profit/(Loss)		1,335,753	876,519
		<u>36,338,953</u>	<u>35,879,719</u>

		Amount in Taka	
		31 December 2024	30 June 2024
16. LONG TERM FINANCE :			
From Al-Arafah Islami Bank Ltd. Secured (Under Hire Purchase Shirkatul Mulk-HPSM)		528,749,408	471,309,764
Current maturity transferred to current liability			
From Al-Arafah Islami Bank Ltd. Secured (Under Hire Purchase Shirkatul Mulk)	Note -21	(31,150,885)	(62,301,769)
LONG TERM FINANCE - net off current maturity		497,598,524	409,007,995
<p>i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial Position @ (SMART + 3.50%) of profit.</p> <p>ii) The loan was taken from Al-Arafah Islami Bank Ltd. against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Mulk.</p> <p>iii) HPSM is repayable in 84 monthly equal installment.</p> <p>iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.</p> <p>v) Information regarding loan fall due after five years.</p>			
Loan fall due from 2 to 5 years		352,499,606	314,206,509
Loan fall due from 6 to more years		145,098,918	94,801,486
		497,598,524	409,007,995
16.A CONSOLIDATED LONG TERM FINANCE :			
The IBN SINA Pharmaceutical Industry PLC		497,598,523	409,007,995
The IBN SINA API Industry Ltd.		211,316,542	121,482,527
		708,915,065	530,490,522
17. EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		1,185,181	1,005,406
Provision during the period		75,155,309	168,958,901
Less: Paid during the period		(74,644,233)	(168,779,126)
		1,696,257	1,185,181
17. A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		1,185,181	1,005,406
Provision during the period		97,022,498	208,717,427
Less: Paid during the period		(96,511,422)	(208,537,652)
		1,696,257	1,185,181
17. B LEASE LIABILITIES:			
Opening Balance		50,336,979	73,750,975
Finance charge		2,133,503	5,810,264
Paid during the period		(14,306,825)	(29,224,260)
Closing balance		38,163,657	50,336,979
Less : Transferred to current maturity		(12,173,322)	(25,538,281)
		25,990,336	24,798,698
<p>i) The company has lease against its head office and its training center located at Mohammadpur, Dhaka.</p> <p>ii) Lease period is upto 31.10.2026</p> <p>iii) Monthly rental payment is Tk.1,851,270</p> <p>iv) Advance amount paid Tk. 11,661,000</p> <p>v) Monthly advance adjustment Tk. 50,000</p>			

Amount in Taka	
31 December 2024	30 June 2024

18. DEFERRED TAX LIABILITY:

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax expense/(income) have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,339,093,707	1,806,120,016	532,973,691	20.00%	106,594,738
Gratuity	76,340,487	74,644,233	(1,696,254)	20.00%	(339,251)
Lease	19,546,784	13,494,333	6,052,450	20.00%	1,210,490
Unrealized gain on marketable securities	(12,623,928)	-	(12,623,928)	10.00%	(1,262,393)
As at 31 December 2024	2,422,357,050	1,894,258,582	524,705,959		106,203,585
Property, plant and equipment	2,402,132,734	1,891,921,442	510,211,292	20.00%	102,042,258
Gratuity	169,964,307	168,779,126	(1,185,181)	20.00%	(237,036)
Lease	7,540,266	13,994,333	(6,454,067)	20.00%	(1,290,813)
Unrealized gain on marketable securities	(9,567,467)	-	(9,567,467)	10.00%	(956,747)
Bad Debt provision	1,359,800	-	(1,359,800)	20.00%	(271,960)
As at 30 June 2024	2,571,429,840	2,074,694,901	491,644,778		99,285,702

DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	106,203,585	99,285,702
Opening balance of deferred tax liability	99,285,702	109,637,275
Total deferred tax expenses/(income)	6,917,882	(10,351,573)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(305,646)	704,930
	6,612,236	(9,646,643)

19 CONSOLIDATED DEFERRED TAX LIABILITY:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,566,874,659	2,027,148,506	539,726,153	20% to 30%	108,613,816
Gratuity	98,207,676	96,511,422	(1,696,254)		(339,251)
Lease	19,039,391	13,713,267	5,326,123		1,070,957
Unrealized gain on marketable securities	(12,623,928)	-	(12,623,928)	10.00%	(1,262,393)
As at 31 December 2024	2,671,497,798	2,137,373,195	530,732,094		108,083,129
Property, plant and equipment	2,628,798,080	2,111,901,346	516,896,734	20% to 27.50%	103,762,047
Gratuity	209,722,833	208,537,652	(1,185,181)	27.50%	(237,036)
Accrued profit on mtdr	1,113,777	-	1,113,777		306,289
Lease	7,237,421	13,994,333	(6,756,912)	10.00%	(1,374,195)
Unrealized gain on marketable securities	(9,567,467)	-	(9,567,467)		(956,747)
Bad Debt provision	1,635,117	100,000	(1,535,117)	20.00%	(320,172)
As at 30 June 2024	2,838,939,761	2,334,533,331	498,965,835		101,180,185

CONSOLIDATED DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	108,083,129	101,180,185
Opening balance of deferred tax liability	101,180,185	109,637,275
Total deferred tax expenses/(income)	6,902,944	(8,457,089)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(305,646)	704,930
	6,597,298	(7,752,160)

20. SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank Ltd. - Secured (Under Composite facilities LC(MP/VT))	908,938,633	1,122,170,475
	908,938,633	1,122,170,475

- Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of Statement of Financial Position @ (SMART +3.50%) of profit and 0.25% commission per quarter to be paid.
- The loan was taken from Al-Arafah Islami Bank Ltd. against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite facilities LC/MPI/MPI TR/UPAS/ Balmuajjal agreement.
- Short term loan is repayable with in twelve months.
- Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.

		Amount In Taka	
		31 December 2024	30 June 2024
20.A CONSOLIDATED SHORT TERM FINANCE :			
A. From Al-Arafah Islami Bank Ltd. - Secured (Under Composite facilities LC(MPI/TR))		908,938,633	1,122,170,475
B. The IBN SINA API Industry Ltd.		28,375,114	120,383,444
		<u>937,313,747</u>	<u>1,242,553,919</u>
21. CURRENT PORTION OF LONG TERM FINANCE:			
i) From Al-Arafah Islami Bank Ltd.-Secured (Under Hire Purchase Shirkatul Melk)		<u>31,174,280</u>	<u>62,301,769</u>
The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank Ltd. and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.			
22. TRADE AND OTHER PAYABLES:			
Payable to suppliers		233,649,662	181,215,838
Provisions	Note-22.1	97,383,276	144,607,133
Accrued expenses		200,070,664	183,670,820
Security money received from employees and others		11,037,604	9,569,964
Workers' profit participation fund & welfare fund		67,125,307	43,132,111
		<u>609,266,513</u>	<u>562,195,866</u>
22.1 PROVISIONS:			
Opening balance		144,607,133	102,620,654
Provisions made during the period		97,383,276	144,607,133
Provisions used during the period		(144,607,133)	(102,620,654)
Closing balance		<u>97,383,276</u>	<u>144,607,133</u>
22.A CONSOLIDATED TRADE AND OTHER PAYABLES :			
Payable to suppliers		372,557,841	260,299,854
Provisions		120,835,980	144,607,133
Accrued expenses		200,070,664	204,021,154
Security money received from employees and others		11,037,604	9,569,964
Workers' profit participation fund & welfare fund		70,777,047	45,486,240
		<u>775,279,136</u>	<u>663,984,345</u>
22.B UNCLAIMED DIVIDEND :			
Opening		39,140,597	31,578,229
Addition		196,834,850	187,461,762
Paid to share holders		(157,920,405)	(174,011,997)
Paid to Capital Market Stabilisation Fund		-	(5,887,397)
		<u>78,055,042</u>	<u>39,140,597</u>
22.2 UNCLAIMED DIVIDEND :			
Year-wise break-up of the above is as follows :			
2020-21		7,246,968	8,652,960
2021-22		13,504,467	15,909,874
2022-23		16,264,012	14,577,763
2023-24		41,039,595	-
		<u>78,055,042</u>	<u>39,140,597</u>
23. INCOME TAX PAYABLES:			
Opening balance		255,866,409	197,886,050
Current tax provision		106,324,177	212,738,107
		<u>362,190,586</u>	<u>410,624,156</u>
Adjusted during the year/period		-	(154,757,747)
		<u>362,190,586</u>	<u>255,866,409</u>
23.A CONSOLIDATED INCOME TAX PAYABLES:			
Opening balance		284,580,559	212,062,009
Current tax expense		110,330,579	227,276,297
		<u>394,911,138</u>	<u>439,338,306</u>
Adjusted during the year/period		-	(154,757,747)
		<u>394,911,138</u>	<u>284,580,559</u>

Amount in Taka		
	For the half-year (1 July 2024 to 31 December 2024)	For the half-year (1 July 2023 to 31 December 2023)
24. REVENUE:		
Local revenue	5,311,628,119	5,061,159,952
Export revenue	98,290,535	101,965,462
	5,409,918,654	5,163,125,414
24.A CONSOLIDATED REVENUE:		
The IBN SINA Pharmaceutical Industry PLC	5,409,918,654	5,163,125,414
The IBN SINA Natural Medicine Ltd.	520,127,637	662,700,711
	5,930,046,291	5,825,826,125
24.B COST OF GOODS SOLD :		
Materials	2,675,262,571	2,552,699,668
Factory Overhead	478,077,285	471,504,149
Depreciation	70,406,748	69,539,059
	3,223,746,603	3,093,742,876
24.C CONSOLIDATED COST OF GOODS SOLD :		
Materials	2,901,518,093	2,855,956,352
Factory Overhead	558,697,069	541,525,802
Depreciation	73,813,668	73,027,284
	3,534,028,829	3,470,509,438
25. ADMINISTRATIVE EXPENSES :		
Salary, Wages & Allowances	63,567,515	58,231,019
Repairs & Maintenance	9,072,702	8,647,226
Travelling & Conveyance	2,627,748	2,532,769
AGM, Fees and Others	1,475,021	1,955,217
Depreciation	13,296,495	13,200,154
Other Expenses	32,081,411	35,379,040
	122,120,893	119,945,426
Less: Expenses for INM	(9,472,142)	(8,396,504)
	112,648,751	111,548,921
25.A CONSOLIDATED ADMINISTRATIVE EXPENSES :		
Salary, Wages & Allowances	67,676,922	61,245,283
Repairs & Maintenance	9,864,673	8,827,425
Travelling & Conveyance	2,627,748	2,534,619
AGM, Fees and Others	1,977,954	2,481,087
Research & Development	221,263	117,712
Depreciation	17,414,296	14,864,672
Other Expenses	34,332,163	35,945,308
	134,115,019	126,016,106

- i) Salary, wages & allowance increased due to increase in manpower, gratuity payment.
- ii) Repairs & Maintenance expense increased due to increase in maintenance of fixed assets to meet business needs.
- iii) Travelling & conveyance increased during the period due to increase travel.
- iv) Research & development expense increased during this period due to meet business needs.
- iv) Depreciation expense during the reporting period increased due to addition of fixed assets .

		Amount In Taka	
		For the half-year (1 July 2024 to 31 December 2024)	For the half-year (1 July 2023 to 31 December 2023)
26. SELLING & DISTRIBUTION EXPENSES :			
Salary, Wages & Allowances		888,657,372	810,289,977
Travelling & Conveyance		4,380,057	4,253,219
Market Survey, & Research and Product development		3,243,031	3,150,886
Field personnel expenses		180,972,115	170,759,817
Sample, Literature & Promotional Expenses		113,936,826	110,886,299
Delivery Expenses		152,426,107	144,517,433
Depreciation		21,031,487	20,175,915
Other Expenses		215,456,981	203,895,211
		1,580,083,776	1,487,908,556
Less: Expenses for INM		(20,805,105)	(26,508,028)
		1,539,278,671	1,441,400,528
26.A CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :			
Salary, Wages & Allowances		1,024,615,340	984,553,425
Travelling & Conveyance		5,938,539	5,816,072
Market Survey & Research and Product development		3,243,031	3,150,886
Field personnel expenses		219,319,478	206,752,856
Sample, Literature & Promotional Expenses		147,351,034	134,135,586
Delivery Expenses		152,426,106	148,493,638
Depreciation		21,243,927	20,395,659
Other Expenses		222,654,144	208,232,704
		1,796,791,600	1,691,530,805
<p>i) Travelling & conveyance increased during the period due to increase travel.</p> <p>ii) Field personal and delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.</p> <p>iii) Depreciation expense during the reporting period increased due to disposal of fixed assets.</p>			
27. WORKERS' P.P FUND & WELFARE FUND :		23,993,196	23,797,883
27.A CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND :			
The IBN SINA Pharmaceutical Industry PLC		23,993,196	23,797,883
The IBN SINA Natural Medicine Ltd.		1,297,811	1,297,811
		25,290,807	25,095,294
28. INCOME TAX EXPENSES:			
Current Tax		108,324,177	110,377,732
Deferred Tax income/(expense)		6,612,236	7,108,884
		112,936,413	117,486,595
Reconciliation of Effective Tax Rate			
Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	479,863,911	20.00%	95,972,782
	479,863,911	20.00%	95,972,782
Non Deductible Expenses		2.16%	10,351,394
Deferred Tax (Income)/expense		1.38%	6,612,236
		23.54%	112,936,413

		Amount in Taka	
		For the half-year (1 July 2024 to 31 December 2024)	For the half-year (1 July 2023 to 31 December 2023)
28.A CONSOLIDATED INCOME TAX EXPENSES:			
Current Tax		110,330,579	118,658,891
Deferred Tax income/(expense)		6,597,297	7,108,864
		116,927,876	125,767,754
Reconciliation of Effective Tax Rate			
Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	412,795,062	20% to 27.50%	104,253,941
	412,795,062	25.26%	104,253,941
Non Deductible Expenses		2.51%	10,351,394
Deferred Tax (income)/expense		1.60%	6,612,236
		29.37%	121,217,572
29. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES :			
Closing value of marketable securities		(12,623,928)	(2,559,368)
Opening value of marketable securities		(9,567,467)	(2,518,168)
		(3,056,462)	(41,200)
30. EARNINGS PER SHARE (EPS) :			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		366,927,499	358,467,058
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
EARNINGS PER SHARE (EPS)		11.74	11.47
30.A CONSOLIDATED EARNINGS PER SHARE (EPS) :			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		295,867,185	372,464,373
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
CONSOLIDATED EARNINGS PER SHARE (EPS) :		9.47	11.92
31. Net Assets Value Per Share (NAV)			
Equity attributable to the owners of the company		3,643,331,325	3,475,989,493
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
Net Assets Value Per Share (NAV)		116.61	111.25
Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earning.			
31.A Consolidated Net Assets Value Per Share (NAV):			
Net Assets Value		3,593,303,060	3,497,480,774
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
Consolidated Net Assets Value Per Share (NAV):		115.01	111.94

Amount in Taka		
	For the half-year (1 July 2024 to 31 December 2024)	For the half-year (1 July 2023 to 31 December 2023)
32. Net Operating Cash Flow Per Share (NOCFPS):		
Net cash provided by operating activities	507,212,831	390,398,327
Divided by weighed average number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
	16.23	12.50
32.A Consolidated Net Operating Cash Flows Per Share (NOCFPS):		
Net cash provided by operating activities	538,814,680	345,339,113
Divided by weighed average number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
	17.25	11.05
33. Reconciliation of net profit with cash flows from operating activities:		
Profit Before Tax (PBT)	479,863,911	475,953,653
Adjustment		
Depreciation	98,184,730	102,915,127
Deferred Tax	6,917,882	7,112,984
Unrealized foreign exchange loss	46,902	(1,543,202)
Share of associate profit/Loss	1,247,355	1,057,515
Gain on sale of Motor Vehicles	-	359,793
Dividend received	1,869,684	696,251
Interest Income	-	(203,415)
Change in operating assets		
Increase in inventory	(27,221,822)	(141,438,744)
Increase in accounts receivables	(5,820,181)	24,571,393
Decrease in advances, deposits and prepayments	6,942,226	241,003
Increase/(decrease) in trade and other payable	58,231,441	41,740,102
Increase/(decrease) in retirement benefit obligation	511,076	511,076
Finance charge	(36,620,120)	(20,611,828)
Tax paid during the period	(76,940,255)	(100,963,381)
	507,212,831	390,398,327
34. Finance Charge:		
Finance charge for long term finance	36,620,120	20,611,828
Finance charge for lease	2,133,503	3,152,106
	38,753,623	23,763,935
34.A Consolidated Finance Charge:		
Finance charge for long term finance	36,620,120	20,611,828
Finance charge for lease	2,133,503	3,152,106
	38,753,623	23,763,935

35. RELATED PARTY DISCLOSURE:

Name of party	Relations hip	Nature of transaction	Transaction		Dec' 2024	June 2024
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		50,000,000	599,999,800	549,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		-	238,169,670	238,169,670
		Administrative Expenses	9,472,142			
		Distribution Expense	20,805,105		-	
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Lease	180,000		180,000	


35.01. NON-CONTROLLING INTEREST

The IBN SINA API Industry Ltd.
The IBN SINA Natural Medicine Ltd.
The IBN SINA Polymer Industry Ltd.

Profit Amount	NCI (%)	Net Amount
(10,813,043)	0.000050	(5)
(60,465,136)	0.001260	(762)
1,314,289	35.000000	460,001
(69,963,890)		459,234


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
25 January 2025


Managing Director


Chairman